Development of a biotin–streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors

Development of a biotin–streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors

KRAS, the most frequently mutated oncogene in human cancers, was considered “undruggable” until the identification of small molecules that bind irreversibly to the mutant reactive cysteine at residue 12. Despite the encouraging anticancer activity of KRASG12C inhibitors in clinical trials, identific...

Full description

Bibliographic Details
Main Authors: Shuang Liu, Junfen Shi, Hongjuan Li, Jijun Li, Yan Zhu, Binghui Li, Yinghui Sun
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:SLAS Discovery
Subjects:
BA-ELISA
KRASG12C inhibitors
High-throughput screening
Cancer drug discovery
Online Access:http://www.sciencedirect.com/science/article/pii/S2472555222000053

Internet

http://www.sciencedirect.com/science/article/pii/S2472555222000053

Similar Items